BioLineRx Ltd. (BLRX)

Develops oncology therapeutics, focusing on cancer therapy and treatment-resistant tumors.

BLRX Stock Quote

Company Report

BioLineRx Ltd., a leading clinical-stage biopharmaceutical development company headquartered in Hevel Modi'in, Israel, specializes in pioneering treatments primarily within the field of oncology.

At the heart of BioLineRx's innovative pipeline is Motixafortide, a peptide with multiple ongoing clinical trials. Motixafortide has completed Phase 3 trials for autologous stem cell mobilization and Phase 2a trials for pancreatic cancer. The peptide is currently being evaluated in Phase 2 trials for metastatic pancreatic adenocarcinoma and Phase 1b trials for acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for solid tumors and acute myeloid leukemia. Additionally, BioLineRx is advancing AGI-134, an immuno-oncology agent in Phase 1/2a trials for solid tumors, and BL-5010, a proprietary pen-like applicator designed for non-surgical removal of skin lesions.

BioLineRx has established strategic collaborations to enhance its development efforts. Collaborations include a partnership with MSD focusing on cancer immunotherapy, joint research with MD Anderson Cancer Center to investigate Motixafortide combined with KEYTRUDA (pembrolizumab) in pancreatic cancer, and a licensing arrangement with Perrigo Company plc for the over-the-counter sale of BL-5010.

Founded in 2003, BioLineRx continues to drive innovation in biopharmaceuticals, leveraging its expertise and strategic partnerships to advance novel therapies that address critical unmet needs in oncology and beyond.

BLRX EPS Chart

BLRX Revenue Chart

Stock Research

HHS LMT PRTA WSFS UTHR XTLB ACU

BLRX Chart

View interactive chart for BLRX

BLRX Profile

BLRX News

Analyst Ratings